We are testing the safety and effectiveness of Sibeprenlimab for people with Immunoglobulin A Nephropathy. This study aims to see how well it works in managing the condition and its impact on kidney health.
We are investigating whether DDAVP can help prevent sodium overcorrection in patients with severe hyponatremia. This study aims to improve safety and outcomes for those experiencing dangerously low sodium levels.
We are comparing a new treatment approach with telemonitoring and education to standard care for patients starting adalimumab. The aim is to see if this helps manage ulcerative colitis more effectively.
We are studying a new gene therapy to see if it is safe and helps adults with Hemophilia B produce a vital clotting factor. The trial will also assess how it affects bleeding events.
We are studying whether a new 20-valent pneumococcal vaccine helps prevent pneumonia in adults aged 65 and older. This trial will assess its effectiveness against specific types of pneumonia caused by certain bacteria.
We are testing a new drug, AZD8421, to see how safe it is and how well it works for people with advanced or metastatic solid tumors. This study will help us understand its effects alone and in combination with other cancer treatments.
We are exploring a new treatment approach for patients with HER2-positive unresectable locally advanced or metastatic breast cancer. This study aims to see how well this treatment works and its safety compared to existing options.
We are studying a new treatment, DB-1303, for patients with HER2-low, hormone receptor-positive metastatic breast cancer. The goal is to see if it works better than standard chemotherapy after previous treatments have failed.
We are providing continued treatment for patients who have benefited from Durvalumab in a previous study. The focus is on monitoring safety and tolerability during this ongoing care.
We are examining the long-term safety and tolerability of ACP-204 in adults with Alzheimer's Disease Psychosis. This study helps us understand how well patients can handle this treatment over time.
We are investigating the long-term safety and effectiveness of BI 1015550 in patients with pulmonary fibrosis who have previously participated in related studies. This study aims to understand how well the treatment is tolerated and its potential benefits.
We are studying whether pancreatic enzyme replacement therapy can help patients with unresectable pancreatic cancer gain weight and improve their nutrition. This may enhance their quality of life and ability to handle chemotherapy.
We are studying the safety of efgartigimod given through IV and injection in children with generalized myasthenia gravis. This trial aims to ensure the treatment is safe and well-tolerated.
We are evaluating the long-term safety and effects of NTLA-2001 in participants who have already received this treatment. This study aims to understand how it impacts their health over time.
We are investigating a new treatment, SP-420, for individuals with transfusion-dependent thalassemia or low-risk myelodysplastic syndromes. The study aims to find the right dose and evaluate its effectiveness in reducing excess iron and its safety.
We are studying whether adding isatuximab to iberdomide helps patients with newly diagnosed multiple myeloma achieve better treatment outcomes after stem cell transplantation.
We are investigating how zolpidem affects people with disorders of consciousness, vision impairments, and healthy volunteers. This study aims to uncover why some individuals respond differently to the medication.
We are evaluating a new inhaler that combines Budesonide, Glycopyrronium, and Formoterol for people with COPD. The goal is to see if it improves heart and lung health compared to current treatments.
We are testing a new treatment for patients with advanced or metastatic solid tumors that have specific genetic changes. The goal is to see how well it works and how it affects patients' daily lives.
We are investigating whether PRGF-Endoret® can effectively reduce pain and enhance quality of life in patients with chronic low back pain due to disc degeneration, compared to standard treatments.